Quantcast

Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry'

Research paper by Singh, J. A.

Indexed on: 17 Jun '16Published on: 10 Jun '16Published in: Annals of the rheumatic diseases



Abstract

Wadstrom et al studied whether tumour necrosis factor (TNF) inhibitors (TNFi) increase the risk of cervical neoplasia in patients with rheumatoid arthritis (RA)'1 Study authors performed a nationwide study using Swedish databases. The main findings from the study were that biologic-naive women with RA had more screenings (HR=1.08; 95% CI 1.06 to 1.10), were at greater risk of cervical intraepithelial neoplasia (CIN) 1 (HR=1.53; 95% CI 1.23 to 1.89) and CIN 2–3 (HR=1.39; 95% CI 1.16 to 1.66), but not of invasive cervical cancer (HR=1.09; 95% CI 0.71 to 1.65), compared with the general Swedish female population without RA. Patients who initiated TNFi therapy had similar screening patterns (HR=1.01; 95% CI 0.98 to 1.05), were not at increased risk of CIN 1 (HR=1.23; 95% CI 0.87 to 1.74), but were at increased risk of CIN 2–3 (HR=1.36; 95% CI 1.01 to 1.82), and invasive cervical cancer (HR=2.10;...